Clinical Trials Logo

Clinical Trial Summary

Patients treated for methamphetamine dependence have high rates of relapse, and no pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d, l-2-[(diphenylmethyl)sulfinyl]acetamide) is a novel wake- and vigilance-promoting agent that is chemically and pharmacologically dissimilar to CNS stimulants. It is well tolerated and has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive function, has been shown to reduce cocaine use in dependent users, and is safe when coadministered with intravenous methamphetamine. We will conduct a randomized dose ranging clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for methamphetamine dependence.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00630097
Study type Interventional
Source California Pacific Medical Center Research Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 2009
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT00887367 - EtOH Interaction Study Phase 1
Completed NCT01036061 - GSK618334 Repeat Dose Study Phase 1
Completed NCT01189799 - Motivational Therapy for Substance Users With Depression N/A
Completed NCT01381133 - Adolescent Outpatient and Continuing Care Study Phase 3
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT01128140 - Efficacy Trial of Warrior Check-Up Phase 2
Completed NCT03767907 - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial N/A
Recruiting NCT05833399 - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn NCT01515917 - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI) N/A
Completed NCT00208143 - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Phase 4
Withdrawn NCT03762798 - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone N/A
Completed NCT03048552 - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 N/A
Active, not recruiting NCT04768920 - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) N/A
Recruiting NCT05410561 - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients N/A
Recruiting NCT05679284 - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn NCT00908206 - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics Phase 1
Recruiting NCT05348317 - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders N/A
Recruiting NCT01741415 - Distress Tolerance Treatment for Substance Users Phase 2
Active, not recruiting NCT01621711 - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2